Swiss Postpartum Hypertension Cohort

Conditions studied

Postpartum Hypertension (PPHT)

About this study

This open label, prospective observational, single-center registry is to study short-, intermediate-and long-term course of postpartum hypertension and predictors/risk factors associated with long term cardiovascular and renal risk. Current disease management strategies will be evaluated.

Interventions

• Other: Data collection for parameters of organ damage (cardiac and renal blood markers) — Blood results will be taken out of next routine venipuncture. Routinely collected standard parameters are a blood count, chemistry panel including renal parameters and electrolytes, lipid profile and a HbA1c as well as albumin/creatinine and protein/creatinine ratio in urine.
• Other: Data collection for blood pressure (BP) — Clinic blood pressure and 24hour BP Measurements
• Other: Home-based blood pressure management (substudy) — Subjects participating in home-based blood pressure management via telemonitoring will receive a free HekaHealth application (App) for the structured assessment of HBPM.
• Other: Biomarker Profiles (substudy) — Substudy where possible cardiac, renal and pregnancy related biomarkers will be additionally analyzed. The following biomarkers will be analyzed: N terminal (NT)-proBNP, Troponin, elevated mid-regional pro-atrial natriuretic peptide (ANP), elevated mid-regional pro adrenomedullin (ADM), soluble fms-like tyrosine kinase (sFlt-1), and placenta growth factor (PlGF).
• Other: Data collection on patient reported outcomes — Data collection on patient reported outcomes (Questionnaire EQ-5D, Questionnaire for App based monitoring )

Primary outcomes

• Frequency of persistent hypertension defined by 24 hours BP measurement (through study completion, an average of 5 years)
• Frequency of persistent hypertension defined by office blood pressure measurement (OBPM, AOBPM) (through study completion, an average of 5 years)
• Frequency of microalbuminuria (through study completion, an average of 5 years)
• Frequency of damage to the retina of the eyes (retinopathy) (through study completion, an average of 5 years)
• Signs of hypertensive heart disease (up to 24 months)
• Frequency of dyslipidemia (through study completion, an average of 5 years)
• Frequency of prediabetes/diabetes (through study completion, an average of 5 years)

Eligibility information

Study locations

• Medical Outpatient Department and Hypertension Clinic, University Hospital Basel, Basel, 4031 Switzerland